Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) EBT (2017 - 2025)

Sutro Biopharma's EBT history spans 9 years, with the latest figure at -$49.2 million for Q3 2025.

  • For Q3 2025, EBT fell 0.84% year-over-year to -$49.2 million; the TTM value through Sep 2025 reached -$200.6 million, down 85.52%, while the annual FY2024 figure was -$225.1 million, 154.06% down from the prior year.
  • EBT for Q3 2025 was -$49.2 million at Sutro Biopharma, down from -$11.5 million in the prior quarter.
  • Across five years, EBT topped out at $46.9 million in Q4 2023 and bottomed at -$70.1 million in Q4 2024.
  • The 5-year median for EBT is -$38.4 million (2023), against an average of -$34.8 million.
  • The largest annual shift saw EBT crashed 282.18% in 2022 before it soared 235.49% in 2023.
  • A 5-year view of EBT shows it stood at -$38.1 million in 2021, then increased by 9.26% to -$34.6 million in 2022, then skyrocketed by 235.49% to $46.9 million in 2023, then tumbled by 249.53% to -$70.1 million in 2024, then increased by 29.81% to -$49.2 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's EBT are -$49.2 million (Q3 2025), -$11.5 million (Q2 2025), and -$69.8 million (Q1 2025).